Home About Products Technology Investor Relations News Contact FINANCIAL RESULTS 2021 Third Quarter 2021 Financial Results Second Quarter 2021 Financial Results First Quarter 2021 Financial Results 2020 Fourth Quarter 2020 Financial Results Third Quarter 2020 Financial Results Second Quarter 2020 Financial Results First Quarter 2020 Financial Results 2019 Fourth Quarter 2019 Financial Results Third Quarter 2019 Financial Results Second Quarter 2019 Financial Results First Quarter 2019 Financial Results 2018 Fourth Quarter 2018 Financial Results Third Quarter 2018 Financial Results Second Quarter 2018 Financial Results First Quarter 2018 Financial Results 2017 Fourth Quarter 2017 Financial Results Third Quarter 2017 Financial Results Second Quarter 2017 Financial Results First Quarter 2017 Financial Results 2016 Fourth Quarter 2016 Financial Results Third Quarter 2016 Financial Results Second Quarter 2016 Financial Results First Quarter 2016 Financial Results 2015 Fourth Quarter 2015 Financial Results Third Quarter 2015 Financial Results Second Quarter 2015 Financial Results First Quarter 2015 Financial Results 2014 Fourth Quarter 2014 Financial Results Third Quarter 2014 Financial Results Second Quarter 2014 Financial Results First Quarter 2014 Financial Results Privacy Information Data Protection Disclaimer Contact CytoSorbents is a leader in critical care immunotherapy. The company is committed to serving the best interests of our patients and their families, our customers, our employees, and our shareholders. Are you an Investor? CytoSorb® is a unique blood purification therapy.The product is currently approved in the European Union and distributed in 58 countries around the world Are you a Healthcare Provider?

Home About Products Technology Investor Relations News Contact INTELLECTUAL PROPERTY The Company holds 16 issued patents in the U.S., some of which have foreign counterparts and additional patent applications pending worldwide. The patents cover materials, processes, and applications of the polymer technology. The company continues to acquire and develop its intellectual property through its own research and development program as well as collaboration with key researchers in academia. Privacy Information Data Protection Disclaimer Contact CytoSorbents is a leader in critical care immunotherapy. The company is committed to serving the best interests of our patients and their families, our customers, our employees, and our shareholders. Are you an Investor? CytoSorb® is a unique blood purification therapy.The product is currently approved in the European Union and distributed in 58 countries around the world Are you a Healthcare Provider?